Investor Relations

Financial Tear Sheet

Financial Tear Sheet

Corporate Profile

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following potentially first-in-class product candidates:

  • Livoletide (AZP-531) for the treatment of Prader-Willi syndrome
  • Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
  • MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause

Stock Quote

Price Change
Volume % Change  
Intraday High 52 Week High
Intraday Low 52 Week Low
Today's Open Currency US Dollar
Previous Close Exchange


Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title
08/12/19
Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results
Printer Friendly Version
08/01/19
Millendo Therapeutics to Participate in August Investor Conferences
Printer Friendly Version
06/18/19
Millendo Therapeutics Announces Departure of Chief Medical Officer
Printer Friendly Version

SEC Filings

Filing date Form
10-Q
4
4
4
4

Primary IR Contact

Stephanie Ascher
Phone: 212-362-1200
E-mail: stephanie@sternir.com

Stock Chart